Advertisement

Lipid-Lowering Drugs

  • Esen Özkaya
  • Kurtuluş Didem Yazganoğlu
Chapter

Abstract

Lipid-lowering drugs include 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins such as simvastatin, atorvastatin, pravastatin, fluvastatin, lovastatin, cerivastatin, rosuvastatin, pitavastatin), fibric acids (fibrates such as fenofibrate, clofibrate, gemfibrozil, bezafibrate, and ciprofibrate), bile acid sequestrants (resins) (cholestyramine, colestipol, and colesevelam), and others (nicotinic acid [niacin], nicotinic acid analogs like xanthinol nicotinate and acipimox, and cholesterol absorption inhibitor such as ezetimibe). Lipid-lowering drugs inhibit different steps in the cholesterol synthesis.

Keywords

Lipid lowering Statins Fibrate Niacin Nicotinic acid Dermatomyositis Lupus erythematosus Eczema Eosinophilic fasciitis Acanthosis nigricans Xerosis Photosensitivity Lichenoid Angioedema/urticaria Alopecia 

References

  1. 1.
    Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21:17–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993;186:248–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Keough GC, Richardson TT, Grabski WJ. Pravastatin-induced lichenoid drug eruption. Cutis. 1998;61:98–100.PubMedGoogle Scholar
  4. 4.
    Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol. 2006;47:57–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Roger D, Rolle F, Labrousse F, Brosset A, Bonnetblanc JM. Simvastatin-induced lichenoid drug eruption. Clin Exp Dermatol. 1994;19:88–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Sebok B, Toth M, Anga B, Harangi F, Schneider I. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin). Acta Derm Venereol. 2004;84:229–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004;30:803–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Inhoff O, Peitsch WK, Paredes BE, Goerdt S, Goebeler M. Simvastatin-induced amyopathic dermatomyositis. Br J Dermatol. 2009;161:206–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Zaraa IR, Labbène I, Mrabet D, Zribi H, Chelly I, Zitouna M, et al. Simvastatin-induced dermatomyositis in a 50-year-old man. BMJ Case Rep. 2011;2011. doi: 10.1136/bcr.02.2011.3832.
  10. 10.
    Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001;110:670–1.PubMedCrossRefGoogle Scholar
  11. 11.
    Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J. 1996;72:694.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Thual N, Penven K, Chevallier JM, Dompmartin A, Leroy D. Fluvastatin-induced dermatomyositis. Ann Dermatol Venereol. 2005;132(12 Pt 1):996–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Zuech P, Pauwels C, Duthoit C, Méry L, Somogyi A, Louboutin A, Veyssier-Belot C. Pravastatin-induced dermatomyositis. Rev Med Interne. 2005;26:897–902.PubMedCrossRefGoogle Scholar
  14. 14.
    de Jong HJ, Tervaert JW, Saldi SR, Vandebriel RJ, Souverein PC, Meyboom RH, et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum. 2011;41:373–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL. French Association of PharmacoVigilance Centres. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus. 2012;21:885–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Noel B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology. 2004;208:276–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45–9.PubMedGoogle Scholar
  18. 18.
    Rüger RD, Simon JC, Treudler R. Subacute-cutaneous lupus erythematosus induced by Simvastatin. J Dtsch Dermatol Ges. 2011;9:54–5.PubMedGoogle Scholar
  19. 19.
    Suchak R, Benson K, Swale V. Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2007;32:589–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Park SJ, Shin JI. Role of interleukin-12 and - 18 in lupus-like syndrome patients with statin use: comment on: Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum. 2012;41:e2–3.PubMedCrossRefGoogle Scholar
  21. 21.
    de Boer EM, Bruynzeel DP. Allergy to pravastatin. Contact Dermatitis. 1994;30:238.PubMedCrossRefGoogle Scholar
  22. 22.
    Peramiquel L, Serra E, Dalmau J, Vila AT, Mascaró JM, Alomar A. Occupational contact dermatitis from simvastatin. Contact Dermatitis. 2005;52:286–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Field S, Bourke B, Hazelwood E, Bourke JF. Simvastatin – occupational contact dermatitis. Contact Dermatitis. 2007;57:282–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Neumark M, Moshe S, Ingber A, Slodownik D. Occupational airborne contact dermatitis to simvastatin, carvedilol, and zolpidem. Contact Dermatitis. 2009;61:51–2.PubMedCrossRefGoogle Scholar
  25. 25.
    Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.Google Scholar
  26. 26.
    Sparsa A, Boulinguez S, Le Brun V, Roux C, Bonnetblanc JM, Bedane C. Acquired ichthyosis with pravastatin. J Eur Acad Dermatol Venereol. 2007;21:549–50.PubMedGoogle Scholar
  27. 27.
    Baykal C, Korkmaz Y, Kavak A. Lovastatin-induced, acquired ichthyosis. Eur J Dermatol. 1996;6:581–3.Google Scholar
  28. 28.
    Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol. 2010;49:1235–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Dugonik A, Belič M, Miljković J. Eosinophilic fasciitis. Acta Dermatovenerol Alp Panonica Adriat. 2003;12:72–5.Google Scholar
  30. 30.
    Choquet-Kastylevsky G, Kanitakis J, Dumas V, Descotes J, Faure M, Claudy A. Eosinophilic fasciitis and simvastatin. Arch Intern Med. 2001;161:1456–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Serrano-Grau P, Mascaró-Galy JM, Iranzo P. Eosinophilic fasciitis after taking simvastatin. Actas Dermosifiliogr. 2008;99:420–1.PubMedCrossRefGoogle Scholar
  32. 32.
    DeGiovanni C, Chard M, Woollons A. Eosinophilic fasciitis secondary to treatment with atorvastatin. Clin Exp Dermatol. 2006;31:131–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Marguery MC, Chouini-Lalanne N, Drugeon C, Gadroy A, Bayle P, Journe F, et al. UV-B phototoxic effects induced by atorvastatin. Arch Dermatol. 2006;142:1082–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Rodríguez-Pazos L, Sánchez-Aguilar D, Rodríguez-Granados MT, Pereiro-Ferreirós MM, Toribio J. Erythema multiforme photoinduced by statins. Photodermatol Photoimmunol Photomed. 2010;26:216–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Holme SA, Pearse AD, Anstey AV. Chronic actinic dermatitis secondary to simvastatin. Photodermatol Photoimmunol Photomed. 2002;18:313–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Granados MT, de la Torre C, Cruces MJ, Piñeiro G. Chronic actinic dermatitis due to simvastatin. Contact Dermatitis. 1998;38:294–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L. Simvastatin-induced lichen planus pemphigoides. Ann Dermatol Venereol. 2003;130(2 Pt 1):187–90.PubMedGoogle Scholar
  38. 38.
    Konig C, Eickert A, Scharfetter-Kochanek K, Krieg T, Hunzelmann N. Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol. 2001;44:689–92.PubMedCrossRefGoogle Scholar
  39. 39.
    Adcock BB, Hornsby LB, Jenkins K. Dermographism: an adverse effect of atorvastatin. J Am Board Fam Pract. 2001;14:148–51.PubMedGoogle Scholar
  40. 40.
    Anliker MD, Wüthrich B. Chronic urticaria to atorvastatin. Allergy. 2002;57:366.PubMedCrossRefGoogle Scholar
  41. 41.
    Hernández N, Peñate Y, Borrego L. Generalized erythematous-violaceous plaques in a patient with a history of dyslipidemia. Interstitial granulomatous drug reaction (IGDR). Int J Dermatol. 2013;52:393–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25:72–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Magro CM, Cruz-Inigo AE, Votava H, Jacobs M, Wolfe D, Crowson AN. Drug-associated reversible granulomatous T cell dyscrasia: a distinct subset of the interstitial granulomatous drug reaction. J Cutan Pathol. 2010;37 Suppl 1:96–111.PubMedCrossRefGoogle Scholar
  44. 44.
    Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis. 2010;13:e29–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Bellini V, Assalve D, Lisi P. Urticarial vasculitis from simvastatin: what is the alternative drug? Dermatitis. 2010;21:223–4.PubMedGoogle Scholar
  46. 46.
    Yamamoto M, Ikeda M, Kodama H, Sano S. Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol. 2008;35:732–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Fernández-Torres R, del Pozo J, Almagro M, Yebra-Pimentel MT, Fernández-Jorge B, Mazaira M, Fonseca E. Skin ulcers and myopathy associated with pravastatin therapy. Clin Exp Dermatol. 2009;34:e237–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Abadir R, Liebmann J. Radiation reaction recall following simvastatin therapy: a new observation. Clin Oncol (R Coll Radiol). 1995;7:325–6.CrossRefGoogle Scholar
  49. 49.
    Rivera Irigoín R, Nicolau Ramis J, Terrasa Sagrista F, Masmiquel Comas L. Rosuvastatin-induced erythema multiforme. Med Clin (Barc). 2013;140:523–4.CrossRefGoogle Scholar
  50. 50.
    Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. JAMA. 1998;279:1613–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Oskay T, Kutluay L. Acute generalized exanthematous pustulosis induced by simvastatin. Clin Exp Dermatol. 2003;28:558–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Perrot JL, Guy C, Bour Guichenez G, Amigues O, Servoz J, Cambazard F. Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin. Ann Dermatol Venereol. 1994;121:817–9.PubMedGoogle Scholar
  53. 53.
    Schindl A, Trautinger F, Pernerstorfer-Schön H, Konnaris C, Hönigsmann H. Porphyria cutanea tarda induced by the use of pravastatin. Arch Dermatol. 1998;134:1305–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Gressier L, Pruvost-Balland C, Dubertret L, Viguier M. Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol. 2009;136:50–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Horton SL, Hashimoto K, Toi Y, Miner JE, Mehregan D, Fligiel A, et al. Spiny keratoderma: a common under-reported dermatosis. J Dermatol. 1998;25:353–61.PubMedGoogle Scholar
  56. 56.
    Adams AE, Bobrove AM, Gilliam AC. Statins and “chameleon-like” cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg. 2010;14:207–11.PubMedGoogle Scholar
  57. 57.
    Mehregan DR, Mehregan DA, Pakideh S. Cheilitis due to treatment with simvastatin. Cutis. 1998;62:197–8.PubMedGoogle Scholar
  58. 58.
    Segal AS. Alopecia associated with atorvastatin. Am J Med. 2002;113:171.PubMedCrossRefGoogle Scholar
  59. 59.
    Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10:337–48.PubMedCrossRefGoogle Scholar
  60. 60.
    Machet L, Vaillant L, Jan V, Lorette G. Fenofibrate-induced photosensitivity: value of photopatch testing. J Am Acad Dermatol. 1997;37:808–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Leenutaphong V, Manuskiatti W. Fenofibrate-induced photosensitivity. J Am Acad Dermatol. 1996;35:775–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Conilleau V, Dompmartin A, Michel M, Verneuil L, Leroy D. Photoscratch testing in systemic drug-induced photosensitivity. Photodermatol Photoimmunol Photomed. 2000;16:62–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Hong JB, Wang SH, Chu CY. Fenofibrate-induced photosensitivity-a case report and literature review. Dermatol Sin. 2009;27:37–43.Google Scholar
  64. 64.
    Serrano G, Fortea JM, Latasa JM, Millan F, Janes C, Bosca F, Miranda MA. Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen. J Am Acad Dermatol. 1992;27:204–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Leenutaphong V. Reply: Fenofibrate-induced photosensitivity: value of photopatch testing. J Am Acad Dermatol. 1997;37:809.CrossRefGoogle Scholar
  66. 66.
    Frendo M, Theuma R, Fava S. Delayed bezafibrate-induced angio-oedema in a 68-year-old man. Br J Clin Pharmacol. 2007;64:560–1.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    de Barrio M, Matheu V, Baeza ML, Tornero P, Rubio M, Zubeldia JM. Bezafibrate-induced anaphylactic shock: unusual clinical presentation. J Investig Allergol Clin Immunol. 2001;11:53–5.PubMedGoogle Scholar
  68. 68.
    Arif MA, Vahrman J. Letter: skin eruption due to clofibrate. Lancet. 1975;2:1202.PubMedCrossRefGoogle Scholar
  69. 69.
    Murata Y, Tani M, Amano M. Erythema multiforme due to clofibrate. J Am Acad Dermatol. 1988;18:381–2.PubMedCrossRefGoogle Scholar
  70. 70.
    Wong SS. Stevens-Johnson syndrome induced by clofibrate. Acta Derm Venereol. 1994;74:475.PubMedGoogle Scholar
  71. 71.
    Sawamura D, Umeki K. Stevens-Johnson syndrome associated with bezafibrate. Acta Derm Venereol. 2000;80:457.PubMedGoogle Scholar
  72. 72.
    Howard EJ, Brown SM. Letter: clofibrate-induced antinuclear factor and lupus-like syndrome. JAMA. 1973;226:1358–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Orgain ES, Bogdonoff MD, Cain C. Clofibrate and androsterone effect on serum lipids. Arch Intern Med. 1967;119:80–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Yung A, Goulden V. Pigmented purpuric dermatosis (capillaritis) induced by bezafibrate. J Am Acad Dermatol. 2005;53:168–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol. 1988;124:854–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Serrao R, Zirwas M, English JC. Palmar erythema. Am J Clin Dermatol. 2007;8:347–56.PubMedCrossRefGoogle Scholar
  77. 77.
    Yang YL, Hu M, Chang M, Tomlinson B. A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. J Clin Pharm Ther. 2013;38:528–32.PubMedCrossRefGoogle Scholar
  78. 78.
    Pontiroli AE, Fattor B, Pozza G, Pianezzola E, Strolin Benedetti M, Musatti L. Acipimox-induced facial skin flush: frequency, thermographic evaluation and relationship to plasma acipimox level. Eur J Clin Pharmacol. 1992;43:145–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Ho SA, Aw DC. Bullous drug eruption secondary to nicotinic acid/laropiprant. Ann Acad Med Singapore. 2012;41:134–5.PubMedGoogle Scholar
  80. 80.
    Mehta V, Vasanth V, Balachandran C. Xanthinol nicotinate induced bullous drug eruption. J Pak Assoc Dermatol. 2009;19:124–5.Google Scholar
  81. 81.
    Williams ML, Feingold KR, Grubauer G, Elias PM. Ichthyosis induced by cholesterol-lowering drugs. Implications for epidermal cholesterol homeostasis. Arch Dermatol. 1987;123:1535–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189:203–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Tromovitch TA, Jacobs PH, Kern S. Acanthosis nigricans-like lesions from nicotinic acid. Arch Dermatol. 1964;89:222–3.PubMedCrossRefGoogle Scholar
  84. 84.
    Coates P, Shuttleworth D, Rees A. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia. Br J Dermatol. 1992;126:412–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Nelson LM. Fixed drug eruptions; a report of two cases, one caused by niacin, the other by cocaine. Calif Med. 1955;82:127–8.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Esen Özkaya
    • 1
  • Kurtuluş Didem Yazganoğlu
    • 1
  1. 1.Department of Dermatology and VenereologyIstanbul University Istanbul Medical FacultyIstanbulTurkey

Personalised recommendations